A Novel Tumor Marker for Anaplastic Lymphoma Kinase (+) Lymphoma: Beta-Human Chorionic Gonadotropin

Creative Commons License


Journal of Oncological Science, vol.9, no.1, pp.46-49, 2023 (Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.37047/jos.2021-84655
  • Journal Name: Journal of Oncological Science
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.46-49
  • Keywords: beta-human chorionic gonadotropin, brentuximab, Lymphoma, prognosis
  • Hacettepe University Affiliated: Yes


Beta-human chorionic gonadotropin (beta-hCG) is an important tumor marker for germ cell tumors. Interestingly in some cases with lymphoma increased beta-hCG levels were detected. The association of beta-hCG expression and mortality in those rare cases isn’t well established. We will present a 40-year-old male who was diagnosed with anaplastic large cell lymphoma with increased beta-hCG levels. Brentuximab-Vedotin monotherapy was started. The beta-hCG level decreased tremendously after initiating of chemotherapy and remained so in the follow up with consecutive chemotherapy cycles. After the treatment 18F-fluorodeoxyglucose (FDG) positron emission tomogra-phy-computed tomography (PET-CT) showed showed tremendous decrease in FDG uptake in comparison to previous PET-CT findings. These findings are correlant with the beta-hCG levels before and after treatment. A brief report of the possible pathophysiological mechanism of beta-hCG expression in lymphoma patients will be presented further.